Abkyu is a Boston-based biotechnology company specializing in the discovery and development of single-domain antibodies, known as VHHs, using advanced in vivo and machine learning methodologies. The company employs proprietary workflows, including next-generation sequencing of target-specific B cells, to identify and characterize VHH candidates that meet stringent biophysical and therapeutic requirements. Abkyu collaborates with partners to provide tailored antibody discovery services, addressing challenges in preclinical research and development. Co-founded by Carolyn M. Boudreau, a virology and immunology expert, the company is committed to advancing human health through innovative antibody solutions.